Tirbanibulin 1% Ointment for the Treatment of Chronically Sun-damaged Skin on the Face
NCT ID: NCT05900258
Last Updated: 2023-11-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
22 participants
INTERVENTIONAL
2023-05-11
2023-11-13
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Tirbanibulin 1% Ointment for the Treatment of Actinic Keratosis on the Back of the Hands
NCT06026358
A Study to Evaluate the Efficacy and Safety of Tirbanibulin Ointment in Adult Participants With Actinic Keratosis
NCT06135415
Patient and Clinician Reported Outcomes for Tirbanibulin Effectiveness and Safety in Actinic Keratosis
NCT05260073
A Study of Tirbanibulin on the Wellbeing of Participants With Actinic Keratoses
NCT05741294
Investigation of the Efficacy and Tolerability of Topical Applied Tirbanibulin on Actinic Keratoses With Downward-directed Proliferation Patterns
NCT06648447
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Treatment
Tirbanibulin
Klisyri® 10 mg/g Ointment (Tirbanibulin) patients receive Tirbanibulin on sun-damaged areas of the face for five days, according to the SmPC.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Tirbanibulin
Klisyri® 10 mg/g Ointment (Tirbanibulin) patients receive Tirbanibulin on sun-damaged areas of the face for five days, according to the SmPC.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosed with sun-damaged skin on the face and AK in the treatment area
* Willing and able to comply with all study procedures
* Use of medically acceptable contraception in males or females of child-bearing potential
* 51 -100 years of age
* Negative pregnancy test at baseline in females of childbearing potential
Exclusion Criteria
* Any contraindication for the IMP, according to the most recent version of the SmPC
* Open lesions of any kind on the face
* Concomitant cutaneous malignancy in treatment area, including but not restricted to squamous skin cancer
* Immune deficiency
* Participation in another clinical trial during the last six months
* Pregnancy or lactation
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Medical University of Graz
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Medizinische Universität Graz
Graz, , Austria
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SunDamage
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.